Cell Therapeutics, Inc. (CTIC) announced that the U.S. Food and Drug Administration's or FDA Oncologic Drugs Advisory Committee or ODAC will review CTI's New Drug Application or NDA for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma on March 22, 2010.
The company said that the meeting was to take place on February 10, 2010, but the FDA postponed the meeting because of severe weather conditions in the Washington, D.C. area. Following the vote at the rescheduled ODAC meeting, the FDA is expected to make a final decision on approval of CTI's NDA for pixantrone by April 23, 2010.
For comments and feedback: editorial@rttnews.com